Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction

References

• CousinsMJLynchMEThe Declaration Montreal: access to pain management is a fundamental human rightPain2011152122673267421995880
   PubMed Web of Science ®Google Scholar
• KnudsenAKBrunelliCKlepstadPWhich domains should be included in a cancer pain classification system? Analyses of longitudinal dataPain2012153369670322264677
   PubMed Web of Science ®Google Scholar
• World Health OrganisationCancer pain relief and palliative careGenevaWorld Health Organisation1996
   Google Scholar
• HanksGWConnoFChernyNExpert Working Group of the Research Network of the European Association for Palliative CareMorphine and alternative opioids in cancer pain: the EAPC recommendationsBr J Cancer200184558759311237376
   PubMed Web of Science ®Google Scholar
• LeppertWPain management in patients with cancer: focus on opioid analgesicsCurr Pain Headache Rep201115427127921479998
   PubMed Web of Science ®Google Scholar
• LussierDHuskeyAGPortenoyRKAdjuvant analgesics in cancer pain managementOncologist20049557159115477643
   PubMed Web of Science ®Google Scholar
• EidelmanAWhiteTSwarmRAInterventional therapies for cancer pain management: important adjuvants to systemic analgesicsJ Natl Compr Canc Netw20075875376017927931
   PubMedGoogle Scholar
• CaraceniAThe EPCRC project to revise the European Association for Palliative Care (EAPC) guidelines on the use of opioids for cancer painPalliat Med201125538939021708843
   PubMed Web of Science ®Google Scholar
• RipamontiCIBandieriERoilaFESMO Guidelines Working GroupManagement of cancer pain: ESMO Clinical Practice GuidelinesAnn Oncol201122Suppl 6vi69vi7721908508
   PubMed Web of Science ®Google Scholar
• CaraceniAHanksGKaasaSEuropean Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC)Use of opioid analgesics in the treatment of cancer pain: evidence–based recommendations from the EAPCLancet Oncol2012132e58e6822300860
   PubMed Web of Science ®Google Scholar
• ChernyNRipamontiCPereiraJExpert Working Group of the European Association of Palliative Care NetworkStrategies to manage the adverse effects of oral morphine: an evidence-based reportJ Clin Oncol20011992542255411331334
   PubMed Web of Science ®Google Scholar
• BrockCOlesenSSOlesenAEFrøkjaerJBAndresenTDrewesAMOpioid-induced bowel dysfunction: pathophysiology and managementDrugs201272141847186522950533
   PubMed Web of Science ®Google Scholar
• KomurcuSNelsonKAWalshDFordRBRybickiLAGastrointestinal symptoms among inpatients with advanced cancerAm J Hosp Palliat Care200219535135512269782
   PubMedGoogle Scholar
• BellTJPanchalSJMiaskowskiCBolgeSCMilanovaTWilliamsonRThe prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1)Pain Med2009101354218721170
   PubMed Web of Science ®Google Scholar
• GálvezRProvencioMCoboMPérezCPérezCCanalJObservational and cross-sectional study of prevalence and severity of the opioid-induced bowel dysfunctionAten Primaria20144613239 Spanish [with English abstract]24332445
   PubMed Web of Science ®Google Scholar
• TutejaAKBiskupiakJStoddardGJLipmanAGOpioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer painNeurogastroenterol Motil201022442443020100280
   PubMed Web of Science ®Google Scholar
• RostiGGattiACostantiniASabatoAFZuccoFOpioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatmentEur Rev Med Pharmacol Sci201014121045105021375137
   PubMed Web of Science ®Google Scholar
• WeschulesDJBainKTReifsnyderJToward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patientsPain Med20067432032916898943
   PubMed Web of Science ®Google Scholar
• AbramowitzLBéziaudNLabrezeLPrevalence and impact of constipation and bowel dysfunction induced by strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS studyJ Med Econ201316121423143324102123
   PubMedGoogle Scholar
• ReimerKHoppMZenzMMeeting the challenges of opioid-induced constipation in chronic pain management – a novel approachPharmacology2009831101718957874
   PubMed Web of Science ®Google Scholar
• DavisMPThe opioid bowel syndrome: a review of pathophysiology and treatmentJ Opioid Manag20051315316117315419
   PubMedGoogle Scholar
• HolzerPTreatment of opioid-induced gut dysfunctionExpert Opin Investig Drugs2007162181194
   PubMed Web of Science ®Google Scholar
• HolzerPOpioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humansNeurosci Lett20043611–319219515135926
   PubMed Web of Science ®Google Scholar
• ShookJEPeltonJTHrubyVJBurksTFPeptide opioid antagonist separates peripheral and central opioid antitransit effectsJ Pharmacol Exp Ther198724324925002824748
   PubMed Web of Science ®Google Scholar
• SykesNPConstipation and diarrhoeaDoyleDHanksGChernyNCalmanKOxford Textbook of Palliative Medicine2nd edOxfordOxford University Press2004483496
   Google Scholar
• BastaSAndersonDLMechanisms and management of constipation in the cancer patientJ Pharmaceut Care Pain Symptom Control1998632140
   Google Scholar
• PotterJWaggAManagement of bowel problems in older people: an updateClin Med20055328929516011223
   PubMed Web of Science ®Google Scholar
• MumfordSPCan high fibre diets improve the bowel function in patients on radiotherapy wardTwycrossRGLackSAControl of Alimentary Symptoms in Far Advanced CancerEdinburghChurchill Livingstone1986183
   Google Scholar
• PoreccaFCowanARaffaRBTallaridaRJKetazocines and morphine: effects on gastrointestinal transit after central and peripheral administrationLife Sci19833215178517906339861
   PubMed Web of Science ®Google Scholar
• ParoladoDSalaMGoriEEffect of intracerebroventricular administration of morphine upon intestinal motility in rat and its antagonism with naloxoneEur J Pharmacol1977464329338590342
   PubMed Web of Science ®Google Scholar
• StewartJJWeisbrodtNWBurksTFCentral and peripheral action of morphine on intestinal transitJ Pharmacol Exp Ther19782053547555660528
   PubMed Web of Science ®Google Scholar
• ThörnSEWattwilMLindbergGSäweJSystemic and central effects of morphine on gastrointestinal motilityActa Anaesthesiol Scand19964021771868848916
   PubMed Web of Science ®Google Scholar
• ThomasJKarverSCooneyGAMethylnaltrexone for opioid-induced constipation in advanced illnessN Engl J Med2008358222332234318509120
   PubMed Web of Science ®Google Scholar
• SlatkinNThomasJLipmanAGMethylnaltrexone for treatment of opioid-induced constipation in advanced illness patientsJ Support Oncol200971394619278178
   PubMedGoogle Scholar
• WoodJDGalliganJJFunction of opioids in the enteric nervous systemNeurogastroenterol Motil200416Suppl 2172815357848
   PubMed Web of Science ®Google Scholar
• RentzAMYuRMüller-LissnerSLeyendeckerPValidation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipationJ Med Econ200912437138319912069
   PubMedGoogle Scholar
• UeberallMAMüller-LissnerSBushmann-KrammCBosseBThe Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patientsJ Int Med Res2011391415021672306
   PubMed Web of Science ®Google Scholar
• RentzAMvan Hanswijck de JongePLeyendeckerPHoppMObservational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countriesCurr Med Res Opin2011271354421083515
   PubMed Web of Science ®Google Scholar
• AbramowitzLBéziaudNCausséCChuberreBAllaertFAPerrotSFurther validation of the psychometric properties of the Bowel Function Index for evaluating opioid-induced constipation (OIC)J Med Econ201316121434144124102611
   PubMedGoogle Scholar
• SlappendelRSimpsonKDuboisDKeiningerDLValidation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back painEur J Pain200610320921715914049
   PubMed Web of Science ®Google Scholar
• MarquisPDe La LogeCDuboisDMcDermottAChassanyODevelopment and validation of the Patient Assessment of Constipation Quality of Life questionnaireScand J Gastroenterol200540554055116036506
   PubMed Web of Science ®Google Scholar
• LewisSJHeatonKWStool form scale a useful guide to intestinal transit timeScand J Gastroenterol19973299209249299672
   PubMed Web of Science ®Google Scholar
• OlesenAEDrewesAMValidated tools for evaluating opioid-induced bowel dysfunctionAdv Ther201128427929421437762
   PubMed Web of Science ®Google Scholar
• RauckRLTreatment of opioid-induced constipation: focus on the peripheral µ-opioid receptor antagonist methylnaltrexoneDrugs201373121297130623881667
   PubMed Web of Science ®Google Scholar
• DestaZWuGMMorochoAMFlockhartDAThe gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6Drug Metab Dispos200230333634311854155
   PubMed Web of Science ®Google Scholar
• GlarePNikolovaTTickooRMillerJBrasMAn overview of antiemetic medications and the considerations for their use in palliative careEur J Palliat Care201219162167
   Google Scholar
• TwycrossRWilcockAGastro-intestinal systemTwycrossRWilcockAPalliative Care Formulary4th edMilton KeynesRadcliffe Publishing2012154
   Google Scholar
• PotetFBouyssouTEscandeDBaróIGastrointestinal prokinetic drugs have different affinity for the human cardiac ether-à-gogo K(+) channelJ Pharmacol Exp Ther200129931007101211714889
   PubMed Web of Science ®Google Scholar
• ChojnackiJItopride in the treatment of kinetic disorders of gastrointestinal tractPrzegl Gastroentorol20116139145 Polish
   Google Scholar
• BourasEPCamilleriMBurtonDDThomfordeGMcKinzieSZinsmeisterARPrucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorderGastroenterology2001120235436011159875
   PubMed Web of Science ®Google Scholar
• TackJvan OutryveMBeyensGKerstensRVandeplasscheLPrucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxativesGut200958335736518987031
   PubMed Web of Science ®Google Scholar
• QuigleyEMPrucalopride: safety, efficacy and potential applicationsTherap Adv Gastroenterol2012512330
   Web of Science ®Google Scholar
• SlootsCERykxACoolsMKerstensRDe PauwMEfficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid–induced constipationDig Dis Sci201055102912292120428949
   PubMed Web of Science ®Google Scholar
• ThayalasekeranSAliHTsaiHHNovel therapies for constipationWorld J Gastroenterol201319458247825124363515
   PubMed Web of Science ®Google Scholar
• CuppolettiJChakrabartiJTewariKMalinowskaDHMethadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currentsCell Biochem Biophys2013661536322918821
   PubMed Web of Science ®Google Scholar
• Müller-LissnerSPharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatmentsExp Opin Drug Metab Toxicol201394391401
   PubMed Web of Science ®Google Scholar
• BusbyRWKesslerMMBartoliniWPPharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipationJ Pharmacol Exp Ther2013344119620623090647
   PubMed Web of Science ®Google Scholar
• LarkinPJSykesNPCentenoCEuropean Consensus Group on Constipation in Palliative CareThe management of constipation in palliative care: clinical practice recommendationsPalliat Med200822779680718838491
   PubMed Web of Science ®Google Scholar
• HolzerPAhmedzaiSHNiederleNOpioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its managementJ Opioid Manag20095314519519662924
   PubMedGoogle Scholar
• LeppertWThe impact of opioid analgesics on the gastrointestinal tract function and the current management possibilitiesContemp Onkol (Pozn)2012162125131
   Web of Science ®Google Scholar
• MercadanteSCasuccioAFulfaroFSwitching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective studyJ Clin Oncol200119112898290411387363
   PubMed Web of Science ®Google Scholar
• AhmedzaiSBrooksDthe TTS-Fentanyl Comparative Trial GroupTransdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of lifeJ Pain Symptom Manage19971352542619185430
   PubMed Web of Science ®Google Scholar
• WirzSWitmmannMSchenkMGastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphineEur J Pain200913773774318977159
   PubMed Web of Science ®Google Scholar
• BaderSDürkTBeckerGMethylnaltrexone for the treatment of opioid-induced constipationExpert Rev Gestroenterol Hepatol2013711326
   PubMed Web of Science ®Google Scholar
• LeppertWRole of oxycodone and oxycodone/naloxone in cancer pain managementPharmacol Rep201062457859120884999
   PubMed Web of Science ®Google Scholar
• MeissnerWSchmidtUHartmannNKathRReinhartKOral naloxone reverses opioid-associated constipationPain200084110510910601678
   PubMed Web of Science ®Google Scholar
• MeissnerWLeyendeckerPMueller-LissnerSA randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipationEur J Pain2009131566418762438
   PubMed Web of Science ®Google Scholar
• NadstawekJLeyendeckerPHoppMPatient assessment of a novel therapeutic approach for the treatment of severe, chronic painInt J Clin Pract20086281159116718705820
   PubMed Web of Science ®Google Scholar
• Targinact 5 mg/2.5 mg, 10 mg/5 mg, 20 mg/10 mg and 40 mg/20 mg prolonged-release tabletsSurrey, EnglandThe electronic Medicines Compendium (eMC) Datapharm Communications Limited [updated November 23, 2012]. Available from: https://www.medicines.org.uk/emc/medicine/22908access%2023%20November%202014Accessed November 23, 2014
   Google Scholar
• RileyJEisenbergEMüller-SchwefeGDrewersAMArendt-NielsenLOxycodone: a review of its use in the management of painCurr Med Res Opin200824117519218039433
   PubMed Web of Science ®Google Scholar
• LiuMWittbrodtELow-dose oral naloxone reverses opioid-induced constipation and analgesiaJ Pain Symptom Manage2002231485311779668
   PubMed Web of Science ®Google Scholar
• Targin^® (oxycodone hydrochloride and naloxone hydrochloride dihydrate) [package insert]Cambridge, UKMundipharma International2011 Polish
   Google Scholar
• SmithKHoppMMundinGNaloxone as a part of a prolonged release oxycodone/naloxone combination reduces oxycodone–induced slowing of gastrointestinal transit in healthy volunteersExpert Opin Investig Drugs2011204427439
   PubMed Web of Science ®Google Scholar
• SamerCFDaaliYWagnerMGenetic polymorphism and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyBr J Pharmacol2010160491993020590588
   PubMed Web of Science ®Google Scholar
• ReimerKHoppMZenzMMeeting the challenges of opioid-induced constipation in chronic pain management – a novel approachPharmacology2009831101718957874
   PubMed Web of Science ®Google Scholar
• SmithKHoppMMundinGSingle- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteersClin Ther200830112051206819108793
   PubMed Web of Science ®Google Scholar
• LeppertWOxycodone/naloxone in the management of patients with pain and opioid–induced bowel dysfunctionCurr Drug Targets201415112413524020972
   PubMed Web of Science ®Google Scholar
• WebsterLRSlevinKANarayanaAEarlCQYangRFentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomesPain Med20131491332134523855816
   PubMed Web of Science ®Google Scholar
• VondrackovaDLeyendeckerPMeissnerWAnalgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic painJ Pain20089121144115418708300
   PubMed Web of Science ®Google Scholar
• SimpsonKLeyendeckerPHoppMFixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer painCurr Med Res Opin200824123503351219032132
   PubMed Web of Science ®Google Scholar
• SmithKHoppMMundinGLow absolute bioavailability of oral naloxone in healthy subjectsInt J Clin Pharmacol Ther201250536036722541841
   PubMed Web of Science ®Google Scholar
• SchangJCDevroedeGBeneficial effects of naloxone in a patient with intestinal pseudoobstructionAm J Gastroenterol19858064074113839105
   PubMed Web of Science ®Google Scholar
• LöwensteinOLeyendeckerPHoppMCombined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomized controlled trialExpert Opin Pharmacother200910453154319243306
   PubMed Web of Science ®Google Scholar
• Sandner-KieslingALeyendeckerPHoppMLong-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic painInt J Clin Pract201064676377420370845
   PubMed Web of Science ®Google Scholar
• LöwensteinOLeyendeckerPLuxEAEfficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trialsBMC Clin Pharmacol2010101220920236
   PubMedGoogle Scholar
• AhmedzaiSHLeppertWJaneckiMLong-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer painSupport Care Cancer Epub2014914
   Web of Science ®Google Scholar
• BlagdenMHaferJDuerrHHoppMBosseBLong-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trialsNeurogastroenterol Motil201426121792180125346155
   PubMed Web of Science ®Google Scholar
• MercadanteSFerreraPAdileCHigh doses of oxycodone-naloxone combination may provide poor analgesiaSupport Care Cancer20111991471147221656338
   PubMed Web of Science ®Google Scholar
• KangJHLeeGWShinSHBrueraEOpioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosisJ Pain Symptom Manage2013462e15e1723680581
   PubMed Web of Science ®Google Scholar
• CloutierCTalianoJO’MahonyWControlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized studyPain Res Manag2013182758223662289
   PubMed Web of Science ®Google Scholar
• HermannsKJunkerUNolteTProlonged-release oxycodone/naloxone in the treatment of neuropathic pain – results from a large observational studyExpert Opin Pharmacother201213329931122224497
   PubMed Web of Science ®Google Scholar
• GattiACasaliMLazzariMProlonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipationAdv Ther2013301415923269562
   PubMed Web of Science ®Google Scholar
• DunlopWUhlRKhanITaylorABartonGQuality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysisJ Med Econ201215356457522313329
   PubMedGoogle Scholar
• ColuzziFRuggeriMClinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal painCurr Med Res Opin20143061139115124528146
   PubMed Web of Science ®Google Scholar
• LazzariMSabatoAFCaldaruloCEffectiveness and tolerability of low–dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysisCurr Med Res Opin201430455556424251879
   PubMed Web of Science ®Google Scholar
• AhmedzaiSHNauckFBar-SelaGBosseBLeyendeckerPHoppMA randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer painPalliat Med2012261506021937568
   PubMed Web of Science ®Google Scholar
• ClemensKEQuednauIKlaschikEBowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancerInt J Clin Pract201165447247821401835
   PubMed Web of Science ®Google Scholar
• SchutterUGrunertSMeyerCSchmidtTNolteTInnovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practiceCurr Med Res Opin20102661377138720380506
   PubMed Web of Science ®Google Scholar
• CuomoARussoGEspositoGForteCAConnolaMMarcassaCEfficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational studyAm J Hosp Palliat Care Epub20131117
   Web of Science ®Google Scholar
• KuusniemiKZöllnerJSjövallSProlonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practiceJ Int Med Res20124051775179323206459
   PubMed Web of Science ®Google Scholar
• ComelonMWisloeff-AaseKRaederJA comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomyActa Anaesthesiol Scand201357450951723301686
   PubMed Web of Science ®Google Scholar
• ShaiovaLRimFFriedmanDJahdiMA review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid–induced constipationPalliat Support Care20075216116617578067
   PubMedGoogle Scholar
• YuanCSIsraelRJMethylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effectsExpert Opin Investig Drugs2006155541552
   PubMed Web of Science ®Google Scholar
• SobczakMSalagaMStorrMAFichnaJPhysiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectivesJ Gastroenterol2014491244523397116
   PubMed Web of Science ®Google Scholar
• YuanCSFossJFOsinskiJToledanoARoizenMFMossJThe safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit timeClin Pharmacol Ther19976144674759129564
   PubMed Web of Science ®Google Scholar
• YuanCSFossJFO’ConnorMEffects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit timeClin Pharmacol Ther200067439840410801249
   PubMed Web of Science ®Google Scholar
• YuanCSClinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effectsJ Support Oncol200422119122
   Google Scholar
• AbarcaFMSaclaridesTJBrandMIA review of the treatment of opioid-induced constipation with methylnaltrexone bromideClin Med Insight: Ther201025360
   Google Scholar
• KotakeANKuwaharaSKBurtonEMcCoyCEGoldbergLIVariations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humansXenobiotica19891911124712542618077
   PubMed Web of Science ®Google Scholar
• ChandrasekaranATongZLiHMetabolism of intravenous methylnaltrexone in mice, rats, dogs, and humansDrug Metab Dispos201038460661620053817
   PubMed Web of Science ®Google Scholar
• McNicolEBoyceDBSchumannRCarrDEfficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trialsPain Med20089663465918828197
   PubMed Web of Science ®Google Scholar
• McNicolEDBoyceDSchumannRCarrDBMu-opioid antagonists for opioid-induced bowel dysfunctionCochrane Database Syst Rev2008162CD00633218425947
   PubMedGoogle Scholar
• CandyBJonesLGoodmanMLDrakeRTookmanALaxatives or methylnaltrexone for the management of constipation in palliative care patientsCochrane Database Syst Rev2011191CD00344821249653
   PubMedGoogle Scholar
• FordACBrennerDMSchoenfeldPSEfficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysisAm J Gastroenterol2013108101566157223752879
   PubMed Web of Science ®Google Scholar
• MoermanIFranckPCamuFEvaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidencesActa Anaesthsiol Belg1995463–4127132
   Google Scholar
• PortenoyRKThomasJMoehl BoatwrightMLSubcutaneous methylnaltrexone for the treatment of opioid–induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging studyJ Pain Symptom Manage200835545846818440447
   PubMed Web of Science ®Google Scholar
• ChamberlainBHCrossKWinstonJLMethylnaltrexone treatment of opioid-induced constipation in patients with advanced illnessJ Pain Symptom Manage200938568369019713070
   PubMed Web of Science ®Google Scholar
• ClemensKEKlaschikEManaging opioid-induced constipation in advanced illness: focus on methylnaltrexone bromideTher Clin Risk Manag20106778220234787
   PubMed Web of Science ®Google Scholar
• DeibertPXanderCBlumHEBeckerGMethylnaltrexone: the evidence for its use in the management of opioid-induced constipationCore Evid2010424725820694079
   PubMedGoogle Scholar
• RELISTOR (methylnaltrexone bromide) Subcutaneous Injection [prescribing information]Tarrytown, NYProgenics Pharmaceuticals, Inc [updated September 2014]. Available from: http://cdn.salix.com/shared/pi/relistor-pi.pdfAccessed November 23, 2014
   Google Scholar
• LipmanAGKarverSKooneyGAStamblerNIsraelRJMethylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension studyJ Pain Palliat Care Pharmacother201125213614521657861
   PubMedGoogle Scholar
• SlatkinNELynnRSuCWangWIsraelRJCharacterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trialsJ Pain Symptom Manage201142575476022045373
   PubMed Web of Science ®Google Scholar
• StettlerAZulianGBUnexpected side effect of methylnaltrexoneJ Palliat Med20131610116823984635
   PubMed Web of Science ®Google Scholar
• MackeyACGreenLGreenePAviganMMethylnaltrexone and gastrointestinal perforationJ Pain Symptom Manage2010401e1e320619194
   PubMedGoogle Scholar
• WatkinsJEckmannKRMaceMLRogersJLangleyGSmithWUtilization of methylnaltrexone (Relistor) for opioid-induced constipation in an oncology hospitalPT20113613336
   Google Scholar
• CentenoCCarranzaOZuriarrainYA prospective study of methylnaltrexone for opioid-induced constipation in advanced illness: should we use it or not?J Pain Symptom Manage2013465e1e324176612
   PubMed Web of Science ®Google Scholar
• MichnaEBlonskyERSchulmanSSubcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, non-malignant pain: a randomized controlled studyJ Pain201112555456221429809
   PubMed Web of Science ®Google Scholar
• IyerSSRandazzoBPTzanisELEffect of subcutaneous methylnaltrexone on patient-reported constipation symptomsValue Health201114117718321211500
   PubMed Web of Science ®Google Scholar
• MichnaEWeilAJDuerdenMEfficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysisPain Med20111281223123021810165
   PubMed Web of Science ®Google Scholar
• YuanCSFossJFO’ConnorMMethylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trialJAMA2000283336737210647800
   PubMed Web of Science ®Google Scholar
• RodriguesAWongCMattiussiAAlexanderSLauEDupuisLLMethylnaltrexone for opioid-induced constipation in pediatric oncology patientsPediatr Blood Cancer201360101667167023766091
   PubMed Web of Science ®Google Scholar
• YuCSChunHKStamblerNSafety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trialsDis Col Rect2011545570578
   PubMed Web of Science ®Google Scholar
• DiegoLAtayeeRHelmonsPHsiaoGvon GuntenCFNovel opioid antagonists for opioid-induced bowel dysfunctionExpert Opin Investig Drugs201120810471056
   PubMed Web of Science ®Google Scholar
• WebsterLDharSEldonMMasuokaLLappalainenJSostekMA phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipationPain201315491542155023726675
   PubMed Web of Science ®Google Scholar
• CheyWDWebsterLSostekMLappalainenJBarkerPNTackJNaloxegol for opioid-induced constipation in patients with noncancer painN Engl J Med2014370252387239624896818
   PubMed Web of Science ®Google Scholar
• MOVANTIK is now FDA approved [webpage on the Internet]Wilmington, DEAstraZeneca2014 [updated September 2014]. Available from: https://www.movantikhcp.com/Accessed November 23, 2014
   Google Scholar
• PaulsonDMKennedyDTDonovickRAAlvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction – a 21-day treatment-randomized trialJ Pain20056318419215772912
   PubMed Web of Science ®Google Scholar
• BüchlerMWSeilerCMMonsonJRClinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical studyAliment Pharmacol Ther200828331232519086236
   PubMed Web of Science ®Google Scholar
• LudwigKEnkerWEDelaneyCPGastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathwayArch Surg2008143111098110519015469
   PubMed Web of Science ®Google Scholar
• Entereg (alvimopan) capsulesDetailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)Silver Spring, MDUS Food and Drug Administration [updated October 2013]. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/ucm194328.htmAccessed July 22, 2014
   Google Scholar
• VickeryRWebsterLLiY-PNo evidence of analgesic interference or CNS opioid withdrawal for TD-1211 in a Phase 2b study in Opioid-Induced Constipation (OIC)Poster presented at: The American Pain Society 32nd Annual Scientific MeetingMay 8–11; 2013New Orleans, LA
   Google Scholar
• MoriTShibasakiYMatsumotoKMechanisms that underlie µ-opioid receptor agonist-induced constipation: differential involvement of µ-opioid receptor sites and responsible regionsJ Pharmcol Exp Ther201334719199
   PubMed Web of Science ®Google Scholar